Keyphrases
Preserved Ejection Fraction
100%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Dapagliflozin
100%
Left Ventricular Ejection Fraction
83%
Cardiovascular Mortality
66%
Confidence Interval
50%
Worsening Heart Failure
50%
Hazard Ratio
50%
Heart Failure Death
50%
Placebo Groups
50%
Heart Failure Hospitalization
33%
Patients with Heart Failure
33%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
33%
Placebo
16%
Once-daily
16%
Patients with Diabetes
16%
AstraZeneca
16%
Adverse Events
16%
Symptom Burden
16%
Hospitalization Risk
16%
Without Diabetes
16%
Patients with Chronic Heart Failure
16%
Time-to-event Analysis
16%
Combined Risk
16%
Total Events
16%
Unplanned Hospitalizations
16%
Mildly Reduced Ejection Fraction
16%
Medicine and Dentistry
Ejection Fraction
100%
Congestive Heart Failure
100%
Dapagliflozin
100%
Heart Left Ventricle Ejection Fraction
50%
Cardiovascular System
40%
Placebo
40%
Hazard Ratio
30%
Sodium Glucose Cotransporter 2 Inhibitor
20%
Diabetes
10%
Adverse Event
10%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Dapagliflozin
100%
Placebo
40%
Sodium Glucose Cotransporter 2 Inhibitor
20%
Adverse Event
10%